Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance, suggesting that tissue-specific activation of FXR may be a novel approach to treat NAFLD. Here, NR1H4 is linked to obesity due to melanocortin 4 receptor deficiency.